Business
Conavi Medical Announces Uplisting to OTCQB Venture Market
- E xpected to enhance visibility and access to U.S. investors - ...
About this update from Conavi Medical Corp.
[{"type":"text","content":"Conavi Medical Announces Uplisting to OTCQB Venture Market\n\n\n\n\n\n -\n \n\n\n\n E\n \n\n\n\n\n xpected to enhance visibility and access to U.S. investors\n \n\n\n\n\n\n\n -\n \n\n\n\n\n Trading to commence on March 6, 2025\n \n\n\n\n\n TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“\n \n Conavi Medical\n \n ” or the “\n \n Company\n \n ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its common shares have been approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading set to commence on March 6, 2025. The ticker symbol will remain CNVIF, and no action is needed by shareholders. Trading on the OTCQB is expected to complement the Company's existing listing on the TSX Venture Exchange.\n \n\n “As we move toward commercial launch of our next-generation Novasight system, we’re pleased to increase investor transparency and visibility with this uplisting,” said Thomas Looby, Conavi Medical’s CEO. “We believe this step will increase our exposure to the U.S. investment community and broaden our investor base.”\n \n\n Operated by the OTC Markets Group, the OTCQB Venture Market is a U.S. trading platform designed for developing and entrepreneurial-stage companies. The Securities and Exchange Commission considers the OTCQB to be an “established public market” for determining the public market price when registering securities for resale. Companies listed on the OTCQB are current in their reporting and undergo an annual verification and management certification process. Additional information about the OTC Markets Group Inc. and the OTCQB can be found at\n \n otcmarkets.com\n \n .\n \n\n\n About Conavi Medical\n \n\n Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) ...